Endocrine Practice最新文献_第3页

Info for Readers/Subscription page 读者信息/订阅页面

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/S1530-891X(25)00113-2

引用次数: 0

Central Hypothyroidism: Advances in Etiology, Diagnostic Challenges, Therapeutic Targets, and Associated Risks 中枢性甲状腺功能减退：病因、诊断挑战、治疗靶点和相关风险的进展。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.02.004

Pedro Iglesias MD

{"title":"Central Hypothyroidism: Advances in Etiology, Diagnostic Challenges, Therapeutic Targets, and Associated Risks","authors":"Pedro Iglesias MD","doi":"10.1016/j.eprac.2025.02.004","DOIUrl":"10.1016/j.eprac.2025.02.004","url":null,"abstract":"<div><h3>Objective</h3><div>Central hypothyroidism is a rare disorder resulting from impaired thyroid hormone production due to deficiencies in TSH secretion from the pituitary or TRH secretion from the hypothalamus. This review aims to summarize recent advances in the etiology, diagnosis, and treatment of central hypothyroidism, with an emphasis on diagnostic and therapeutic challenges.</div></div><div><h3>Methods</h3><div>A comprehensive review of the literature was conducted, focusing on genetic and acquired causes, particularly those related to hypothalamic–pituitary tumors and the effects of surgical and radiotherapeutic interventions. Diagnostic approaches and treatment strategies, including levothyroxine therapy and monitoring, are analyzed.</div></div><div><h3>Results</h3><div>Early diagnosis requires simultaneous measurement of free T4 and TSH to prevent neurological sequelae, especially in congenital cases. Central hypothyroidism is associated with risks such as growth and developmental impairment, as well as metabolic and cardiovascular disturbances. Levothyroxine therapy is crucial for correcting hormonal deficits and improving patient outcomes; however, careful dosing is necessary to avoid potential complications, particularly in vulnerable populations.</div></div><div><h3>Conclusions</h3><div>Personalized treatment and continuous monitoring are essential to optimize clinical outcomes and enhance the quality of life in affected individuals. A thorough understanding of central hypothyroidism's etiology and management is necessary to improve early detection and therapeutic strategies.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 650-659"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Impact of Thyroid Eye Disease on Quality of Life: Insights From a Retrospective Cohort Study 甲状腺眼病对生活质量的长期影响：来自回顾性队列研究的见解

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.02.003

Jan Schovanek MD, PhD , Martin Radvansky PhD , Marta Karhanova MD, PhD, FEBO , Marie Bolacka MD , Klara Pekarova MD , Roman Dohnal MD , Martin Radvansky Jr. MSc , Milos Kudelka PhD , Eva Kriegova PhD , David Karasek MD, PhD

{"title":"Long-Term Impact of Thyroid Eye Disease on Quality of Life: Insights From a Retrospective Cohort Study","authors":"Jan Schovanek MD, PhD , Martin Radvansky PhD , Marta Karhanova MD, PhD, FEBO , Marie Bolacka MD , Klara Pekarova MD , Roman Dohnal MD , Martin Radvansky Jr. MSc , Milos Kudelka PhD , Eva Kriegova PhD , David Karasek MD, PhD","doi":"10.1016/j.eprac.2025.02.003","DOIUrl":"10.1016/j.eprac.2025.02.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Thyroid eye disease (TED) seriously affects patients’ quality of life (QoL), even if the disease is stable and nonactive. Data on clinical factors negatively influencing the QoL of patients with TED and long-term outcomes are limited. This study aims to evaluate the lasting impact of TED on QoL, focusing on the effects of previous TED treatments and identifying factors influencing long-term outcomes.</div></div><div><h3>Methods</h3><div>A retrospective cohort study included 151 patients treated for active, moderate-to-severe and severe TED, with a mean follow-up of 8 years.</div></div><div><h3>Results</h3><div>Higher clinical activity scores at diagnosis correlated with lower QoL scores. Thyroidectomy before immunosuppressive treatment was associated with lower QoL and an increased likelihood of orbital decompression. Any disease progression necessitating second-line treatments also negatively affected QoL. A decrease in thyrotropin receptor antibodies during active treatment and early treatment initiation positively affected visual functioning. Time-dependent regression analysis demonstrated no significant trend in QoL changes over time.</div></div><div><h3>Conclusion</h3><div>Our data reveal that disease severity, the timing of interventions and disease progression contribute to less favorable long-term QoL outcomes, extending years beyond active treatment. Early and accurate diagnosis and appropriate treatment can minimize poor long-term QoL in patients with TED.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 607-613"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study 钠-葡萄糖共转运蛋白2抑制剂治疗后2型糖尿病尿路感染患者的心血管结局：一项多中心观察研究

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.02.014

Tse-Lun Hsu MD , Feng-Hsuan Liu MD , Jui-Hung Sun MD , Yi-Hsuan Lin MD , Chih-Yiu Tsai MD , Chia-Hung Lin MD, PhD

{"title":"Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study","authors":"Tse-Lun Hsu MD , Feng-Hsuan Liu MD , Jui-Hung Sun MD , Yi-Hsuan Lin MD , Chih-Yiu Tsai MD , Chia-Hung Lin MD, PhD","doi":"10.1016/j.eprac.2025.02.014","DOIUrl":"10.1016/j.eprac.2025.02.014","url":null,"abstract":"<div><h3>Objective</h3><div>Urinary tract infection (UTI) is an adverse effect of sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, its effect on cardiovascular outcomes in type 2 diabetes mellitus (T2DM) patients remains unclear.</div></div><div><h3>Methods</h3><div>This multicenter retrospective observational study included diabetes patients who received SGLT2is between January 2016 and January 2019. Major adverse cardiovascular events (MACEs) were defined as a composite of nonfatal myocardial infarction, nonfatal stroke, cardiac death, all-cause death, or hospitalization due to heart failure. Outcomes were compared between patients with and without UTI. Multivariate analyses were conducted to adjust for baseline characteristics that might influence the outcomes.</div></div><div><h3>Results</h3><div>We retrospectively reviewed 8862 T2DM patients who had been treated with SGLT2i. In total, 550 patients were identified as having UTIs and requiring antibiotics after SGLT2i treatment. We followed up on the cardiovascular outcomes for 30 months after SGLT2i treatment. After adjusting significant baseline characters, the UTI group exhibited increased risk of MACE (adjusted hazard ratio [aHR] = 2.03, 95% confidence interval [CI] = 1.60-2.57, <em>P</em> < .0001), heart failure hospitalization (aHR = 1.66, 95% CI = 1.32-2.09, <em>P</em> < .0001), and all-cause mortality (aHR = 2.67, 95% CI = 2.10-3.40), <em>P</em> < .0001).</div></div><div><h3>Conclusion</h3><div>UTI in patients with T2DM post-SLGT2i therapy is associated with an increased risk of MACE for up to 30 months.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 592-598"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adrenocorticotropic Hormone Measured by Immulite 1000 and Elecsys Assay Platforms in Suspected Cases of Hypocortisolism: A Word of Caution 用Immulite1000®和Elecsys®检测平台检测疑似低皮质醇病例的ACTH：一个警告。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.02.018

Arijit Singha MD, DM, Pradip Mukhopadhyay MD, DM, Sujoy Ghosh MD, DM, FRCP

{"title":"Adrenocorticotropic Hormone Measured by Immulite 1000 and Elecsys Assay Platforms in Suspected Cases of Hypocortisolism: A Word of Caution","authors":"Arijit Singha MD, DM, Pradip Mukhopadhyay MD, DM, Sujoy Ghosh MD, DM, FRCP","doi":"10.1016/j.eprac.2025.02.018","DOIUrl":"10.1016/j.eprac.2025.02.018","url":null,"abstract":"<div><h3>Objective</h3><div>Several reports suggested that adrenocorticotropic hormone (ACTH) level measured by Immulite 1000 may be falsely elevated leading to misdiagnosis of etiology of Cushing syndrome. However, when it comes to fallacies of ACTH measurement in suspected cases of hypocortisolism, evidence is limited. We explored the performance of ACTH assays using Immulite 1000 and Elecsys Cobas immunoassay platforms in subjects with hypocortisolism.</div></div><div><h3>Methods</h3><div>In this observational, cross-sectional study, 104 patients with haemoglobin E/beta-thalassemia were subjected to 9 <span>am</span> serum cortisol, direct renin concentration, and plasma aldosterone. Plasma ACTH was measured in Immulite 1000 and Elecsys Cobas platforms. Both 1 μg and 250 μg Synacthen stimulation tests were performed to diagnose adrenal insufficiency.</div></div><div><h3>Results</h3><div>Among 104 patients with haemoglobin E/beta-thalassemia, 34 had primary adrenal insufficiency, 9 had secondary adrenal insufficiency, and 33 had subclinical adrenal insufficiency. Mean plasma ACTH (n = 104) measured by Immulite 1000 and Elecsys was 83.42 ± 63.46 pg/mL versus 52.10 ± 38.14 pg/mL, respectively (<em>P</em> < .001). The values had good correlation (r = 0.341, <em>P</em> < .001); however, the agreement between measured values was not strong (Cohen’s κ = 0.208, <em>P</em> = .001). With regard to the diagnosis of primary adrenal insufficiency, specificity of Immulite 1000 was low compared with Elecsys (27.86% vs 80.32%). Furthermore, 2 patients with secondary adrenal insufficiency had inappropriately elevated ACTH measured at Immulite 1000 assay platform.</div></div><div><h3>Conclusion</h3><div>Use of Immulite 1000 platform may result in falsely elevated ACTH values. Physicians should exercise caution while interpreting the results and repeat test using a different assay platform may be considered.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 620-624"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Polycystic Ovary Syndrome in East Asia: A Review and Meta-Analysis 东亚多囊卵巢综合征患者代谢功能障碍相关脂肪变性肝病的危险因素：综述和荟萃分析

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.01.011

Zhao Wu , Guining Liang , Ying Zhang PhD , Renyuan Li MD

{"title":"Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Polycystic Ovary Syndrome in East Asia: A Review and Meta-Analysis","authors":"Zhao Wu , Guining Liang , Ying Zhang PhD , Renyuan Li MD","doi":"10.1016/j.eprac.2025.01.011","DOIUrl":"10.1016/j.eprac.2025.01.011","url":null,"abstract":"<div><h3>Objectives</h3><div>The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in women with polycystic ovary syndrome (PCOS). Epidemiologic literature regarding the risk factors for MASLD in PCOS women in East Asia is inconsistent. Studies of PCOS and MASLD in East Asia are restricted by limited data and various biases. Therefore, this meta-analysis was conducted.</div></div><div><h3>Methods</h3><div>This meta-analysis followed the MOOSE statement. Relevant studies published before July 13, 2023 were retrieved from the PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, Wan Fang, KISS, and Japan medical online databases. The related data were extracted, and the weighted mean difference, odds ratios and 95% confidence intervals were calculated.</div></div><div><h3>Results</h3><div>Twenty-four studies were included. Through univariate analysis, age, body mass index, waist-to-hip ratio (WHR), blood pressure, alanine transaminase, aspartate transaminase, fasting blood glucose, fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), 2-hour postprandial blood glucose, 2 hour insulin, HBA1C, low-density lipoprotein cholesterol, triglyceride, total cholesterol, and testosterone were notably higher in PCOS women with MASLD, with high-density lipoprotein cholesterol markedly lower in PCOS women with MASLD. According to the pooled multivariate analysis, the WHR (<em>P</em> < .001), testosterone (<em>P</em> = .034), and HOMA-IR (<em>P</em> = .02) were substantially greater in PCOS women with MASLD.</div></div><div><h3>Conclusion</h3><div>MASLD is associated with obesity, IR, and hyperandrogenemia among PCOS women in East Asia. The abnormality of WHR, HOMA-IR, and testosterone suggested early screening of MASLD in this population.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 668-676"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thyroid Dysfunction Following Thermal Ablation of Large Solid and Solid-Predominant Thyroid Nodules 大实性和实性甲状腺结节热消融后的甲状腺功能障碍。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.01.004

Lanyan Qiu MD , Yuqing Huang MD , Yueyue Ge MD , Xinyu Zhao MD , Chen Su MD , Yu Yang MD , Yunyun Dong MD , Jing Liu MD , Xia Ma MD , Ran Li MD , Linxue Qian MD , Xianquan Shi MD

{"title":"Thyroid Dysfunction Following Thermal Ablation of Large Solid and Solid-Predominant Thyroid Nodules","authors":"Lanyan Qiu MD , Yuqing Huang MD , Yueyue Ge MD , Xinyu Zhao MD , Chen Su MD , Yu Yang MD , Yunyun Dong MD , Jing Liu MD , Xia Ma MD , Ran Li MD , Linxue Qian MD , Xianquan Shi MD","doi":"10.1016/j.eprac.2025.01.004","DOIUrl":"10.1016/j.eprac.2025.01.004","url":null,"abstract":"<div><h3>Objectives</h3><div>Thermal ablation (TA) is an alternative to lobectomy for thyroid nodules (TNs). While it is believed that thyroid function remains stable after TA for cystic TNs, the impact of TA on solid TNs, especially the large ones, is less explored. This study investigates changes in thyroid hormones after TA in patients with solid-predominant TNs and identifies potential risk factors for thyroid dysfunction after TA.</div></div><div><h3>Methods</h3><div>Euthyroid patients with solid-predominant TNs (≥ 80% solid) were enrolled. The volume, diameter, and cytopathology of TNs were assessed before TA. TA was performed using either microwave or radiofrequency ablation. Thyroid hormone levels were measured at 1 week and 1, 3, 6, and 12 months after TA.</div></div><div><h3>Results</h3><div>Seventy-seven euthyroid patients with TNs were included. The euthyroid rate dropped to 70.1% at 1 week after TA but improved to over 90% by 1 month and returned to 100% by 12 months. At 1 week after TA, subclinical hyperthyroidism and hyperthyroidism were observed, with elevated thyroxine, free triiodothyronine, free thyroxine, and thyroglobulin antibody levels, along with decreased thyroid-stimulating hormone (TSH) levels. The diameter and total volume of TNs were positively correlated with thyroid dysfunction, while TSH-baseline was negatively correlated with thyroid dysfunction 1 week after TA. A larger diameter and lower baseline TSH were identified as independent risk factors for thyroid dysfunction.</div></div><div><h3>Conclusions</h3><div>TA may cause short-term thyroid dysfunction, especially in patients with large TNs. Monitoring of thyroid hormone levels is recommended from 1 week to 3 months after TA to manage potential thyroid dysfunction effectively.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 599-606"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetes and Lipids: A Review and Update on Lipid Biomarkers and Cardiovascular Risk 糖尿病和脂质：脂质生物标志物和心血管风险的综述和最新进展。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.03.011

Yumiko Tsushima MD , Betul Hatipoglu MD

{"title":"Diabetes and Lipids: A Review and Update on Lipid Biomarkers and Cardiovascular Risk","authors":"Yumiko Tsushima MD , Betul Hatipoglu MD","doi":"10.1016/j.eprac.2025.03.011","DOIUrl":"10.1016/j.eprac.2025.03.011","url":null,"abstract":"<div><h3>Objective</h3><div>To review existing and new evidence regarding the relationship between diabetes and dyslipidemia and to provide an update of the lipid biomarkers used to assess cardiovascular risk and the current guidelines reflecting these changes.</div></div><div><h3>Methods</h3><div>We conducted a literature review pertaining to diabetes and lipids using the MEDLINE/PubMed database. We reviewed articles in English and primarily published between 1994 and early 2025. Also included are guidelines published by professional organizations who are recognized nationally or internationally in the fields of diabetes, lipids, and cardiovascular disease.</div></div><div><h3>Results</h3><div>Studies evaluating the relationship between diabetes and hypertriglyceridemia have provided practice-changing evidence. Lipid markers such as apolipoprotein B, non–high-density lipoprotein cholesterol, and lipoprotein (a), as well as the concept of lipid variability have emerged as treatment targets.</div></div><div><h3>Conclusion</h3><div>Over the past 30 years, non–low-density lipoprotein cholesterol lipid markers have been identified to further stratify individuals with diabetes who are at risk for future cardiovascular events. Treatment targets and pharmacological therapy have been studied and continue to be updated.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 677-685"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Daily Insulin Dose Adjustments and Glycemic Control in Noncritically Ill Hospitalized Hyperglycemic Patients: A Retrospective Cohort Study 非危重住院高血糖患者每日胰岛素剂量调整与血糖控制之间的关系：一项回顾性队列研究

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.01.008

Sarah Kanbour MD , Andrew D. Zale MD , Jalene Y. Shim MD, Mohammed S. Abusamaan MD, Nestoras Mathioudakis MD MHS

{"title":"Association Between Daily Insulin Dose Adjustments and Glycemic Control in Noncritically Ill Hospitalized Hyperglycemic Patients: A Retrospective Cohort Study","authors":"Sarah Kanbour MD , Andrew D. Zale MD , Jalene Y. Shim MD, Mohammed S. Abusamaan MD, Nestoras Mathioudakis MD MHS","doi":"10.1016/j.eprac.2025.01.008","DOIUrl":"10.1016/j.eprac.2025.01.008","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy of daily insulin dose increases in managing inpatient hyperglycemia.</div></div><div><h3>Methods</h3><div>Retrospective study of patients discharged from 2 urban academic medical centers and 3 large suburban community hospitals between 2015 and 2019 who received ≥10 units of basal insulin on any day. On hyperglycemic days (mean glucose ≥180 mg/dL), we categorized the relative insulin dose increases into 4 categories based on percentage changes from the previous day. We further subclassified these categories according to the average blood glucose (BG), total daily dose (TDD), and weight-based dosing quartiles. The primary goal was achieving an average BG of ≤160 mg/dL without subsequent hypoglycemia (≤70 mg/dL) on the following day.</div></div><div><h3>Results</h3><div>From 25 186 hospital admissions, we collected data on 240 556 hospital days and 63 033 hyperglycemic index days. The median age was 64, with 53.4% being male and 52.1% White. The median BG level was 222.7 mg/dL. Type 2 diabetes was coded in 54.7%, while 36.3% lacked a diabetes code but received basal insulin. Insulin dose adjustments showed a strong correlation with glycemic control; specifically, a 44% to 100% increase in TDD was significantly more likely to achieve the primary outcome, compared to a TDD increase of 10% to 22%. This trend remained consistent across varied BG ranges and dosing categories.</div></div><div><h3>Conclusion</h3><div>More intensive insulin adjustments may be required for inpatient hyperglycemia compared to the typical 10% to 20% recommendation. Prospective studies are needed to validate and build upon these retrospective findings.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 5","pages":"Pages 557-563"},"PeriodicalIF":3.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative and Periprocedural Management of Once-Weekly Insulin Treated Patients 每周一次胰岛素治疗患者的围手术期和围手术期管理。

IF 3.7 3区医学

Endocrine Practice Pub Date : 2025-05-01 DOI: 10.1016/j.eprac.2025.01.009

Robyn L. Houlden MD, FRCPC , Jeremy D. Gilbert MD, FRCPC , Tayyab S. Khan MD, MASc, MPH, FRCPC , C. David Mazer MD, FRCPC , Jill Trinacty MD, FRCPC, ABOM , Subodh Verma MD, PhD, FRCSC, FAHA , Ronald M. Goldenberg MD, FRCPC

引用次数: 0